First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maint...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Susana, Gonzalez-Martin, Antonio, Harter, Philipp, Lorusso, Domenica, Moore, Kathleen N, Oaknin, Ana, Ray-Coquard, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783599/
https://www.ncbi.nlm.nih.gov/pubmed/33310779
http://dx.doi.org/10.1136/esmoopen-2020-001110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783599/
https://www.ncbi.nlm.nih.gov/pubmed/33310779
http://dx.doi.org/10.1136/esmoopen-2020-001110

Ejemplares similares